^
    Back
    Association details:
    Biomarker:NRAS mutation
    Cancer:Endometrial Cancer
    Drug:Gomekli (mirdametinib) (MEK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors

    Excerpt:
    ...- Part B: NRAS mutated solid tumors must have a known mutation status and a histologically or cytologically confirmed advanced or refractory solid tumor....
    Trial ID:
    NCT03905148
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Clin Cancer Res
    Title:

    PI3K pathway dependencies in endometrioid endometrial cancer cell lines

    Excerpt:
    Five cell lines (21%) were sensitive to the MEK inhibitor PD0325901, and response was significantly associated with the presence of KRAS, HRAS or NRAS mutations (P=0.028) but not with the doubling time of cells (mean sensitive 30.76 ± 0.90h, mean resistant 39.88 ± 4.45h, MWU, P= 0.743).
    DOI:
    10.1158/1078-0432.CCR-12-3815